



DAC
Box 509 A

PTO/SB/21 (02-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	09/842,973
Filing Date	April 27, 2001
First Named Inventor	Benjamin Rovinski
Art Unit	
Examiner Name	
Attorney Docket Number	1038-1142 MIS:ah

09/842,973

RECEIVED

JUL 12 2004

Total Number of Pages in This Submission

11

OFFICE OF PETITIONS

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Technology Center (TC)
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input checked="" type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	Postcard
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	Sequence Listing in computer readable form and hard copy
<input type="checkbox"/> Certified Copy of Priority Document(s)	Remarks	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Michael I. Stewart (Reg. No. 24,973)
Signature	
Date	July 6, 2004

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below

Typed or printed name	Michael I. Stewart		
Signature		Date	July 6, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#15

Applicant : Benjamin Rovinski, et al.
Appl'n. No. : 09/842,883
Filed : April 27, 2001
Title : IMMUNIZING AGAINST HIV INFECTION
Docket No. : 1038-1142 MIS/ah
Date : July 6, 2004

BY COURIER

Mail Stop Petitions
Commissioner of Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
U.S.A.

RECEIVED

JUL 12 2004

OFFICE OF PETITIONS

**RENEWED PETITION TO REVIVE ABANDONED APPLICATION
UNDER 37 CFR 1.137(a)**

Sir:

This Renewed Petition is submitted in response to the Decision on Petition dated May 7, 2004.

The Examiner indicates that the Petition lacked the required reply to the "Notice to Comply with Requirements for Patent Application Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" dated July 10, 2002.

As explained in the Petition submitted March 2, 2004, the Applicants had already complied with this requirement by our letter of November 12, 2001 received in the PTO on November 3, 2001.

However, having regard to the Decision, submitted herewith are:

1. Sequence Listing in computer readable form and hard copy form.

2. Amendment directing entry of the Sequence Listing into the specification

3. It is hereby stated, under the signature of the undersigned, that the content of the paper and computer-readable forms of the Sequence Listing are the same and involve no new matter.

It is submitted that, under the circumstances, this application should be revived.

Respectfully submitted,



Michael I. Stewart
Reg. No. 24,973

Toronto, Ontario, Canada,
(416) 595-1155
FAX No. (416) 595-1163



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Benjamin Rovinski, et al.
Appl'n. No. : 09/842,883
Filed : April 27, 2001
Title : IMMUNIZING AGAINST HIV INFECTION
Grp./A.U. :
Examiner :
Docket No. : 1038-1142 MIS:ah
Date : July 2, 2004

BY COURIER

Mail Stop Sequence
Commissioner of Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
U.S.A.

RECEIVED
JUL 12 2004
OFFICE OF PETITIONS

VOLUNTARY AMENDMENT

Dear Sir:

Please amend this application in the following manner:

In the Disclosure:

Please insert the attached Sequence Listing immediately following page 20 and before the claims.

REMARKS

The Sequence Listing is added to the specification hereby.

Respectfully submitted

Michael I. Stewart
Reg. No. 24,973

Toronto, Ontario, Canada
(416) 595-1155
FAX No. (416) 595-1163



#16

SEQUENCE LISTING

<110> Rovinski, Benjamin
Tartaglia, James
Cao, Shi-Xian
Persson, Roy
Klein, Michel H.

<120> IMMUNIZING AGAINST HIV INFECTION

<130> 1038-1142 MIS

<140> 09/842,883

<141> 2001-04-27

<150> 60/200,011

<151> 2000-04-27

<160> 19

<170> PatentIn Ver. 2.1

<210> 1

<211> 1345

<212> DNA

<213> Human immunodeficiency virus

<400> 1

```
ttttttttcat tatttagaaa ttatgcattt tagatcttta taagcggccg tgattaacta 60
gtcataaaaaa cccgggatcg attctagact cgagggtacc ggatcttaat taattagtca 120
tcaggcaggg cgagaacgag actatctgct cgtaatttaa ttaggtcgac ggatcccca 180
acaaaaacta atcagctatc ggggttaatt aattagttat tagacaaggt gaaaacgaaa 240
ctattttagt cttaattaat tagagcttct ttattctata cttaaaaagt gaaaataaat 300
acaaagggttc ttgagggttg tgttaaattg aaagcgagaa ataatcataa attatttcat 360
tatcgcgata tccgttaagt ttgtatcgta atgccactaa cagaagaagc agagctagaa 420
ctggcagaaa acagagagat tctaaaagaa ccagtacatg gagtgtatta tgacctatca 480
aaagacttaa tagcagaaat acagaagcag gggcaaggcc aatggacata tcaaatttat 540
caagagccat ttaaaaatct gaaaacagga atggagtggg gatttgattc tagattagca 600
tttcatcacg tagctagaga attacatcct gaattttta aaaattgtat ggcaatattc 660
caaagtagca tgacaaaaat cttagagcct tttagaaaac aaaatccaga catagttatc 720
tatcaatata tggatgattt gtatgtagga tctgacttag aaatagggca gcatagaaca 780
aaaatagagg agctgagaca acatctgttg aggtggggac ttacaacccat ggtaggtttt 840
ccagtaacac ctcaagtacc tttaagacca atgacttaca aagcagctgt agatctttct 900
cactttttta aagaaaaagg aggttttaga gggctaattc attctcaacg aagacaagat 960
attcttgatt tgtggattta tcatcacaa ggatattttc ctgattggca gaattacaca 1020
ccaggaccag gagtcagata cccattaacc tttggttggg gctacaagct agtaccatg 1080
attgagactg taccagtaaa attaaagcca ggaatggatg gcccaaaagt taaacaatgg 1140
ccattgacag aagaaaaaat aaaagcatta gtagaaattt gtacagagat ggaaaaggaa 1200
gggaaaattt caaaaattgg gccttaattt ttctgcagcc cgggggatcc tttttatagc 1260
taattagtca cgtaccttg agagtaccac ttcagctacc tcttttgtgt ctcagagtaa 1320
ctttctttta tcaattccaa aacag                                     1345
```

<210> 2

<211> 64

<212> DNA

<213> Human immunodeficiency virus

<400> 2
atcatcatcg gatccccggg tcgcgatatc cgttaagttt gtatcgtaat gaaagtgaag 60
gacc 64

<210> 3
<211> 38
<212> DNA
<213> Human immunodeficiency virus

<400> 3
atcatcatcg gatccccggg ttatagcaaa gccctttc 38

<210> 4
<211> 28
<212> DNA
<213> Human immunodeficiency virus

<400> 4
gcactcttct atagtcttga tatagtac 28

<210> 5
<211> 33
<212> DNA
<213> Human immunodeficiency virus

<400> 5
agccggggcg cagaaatgta tgggaattgg cac 33

<210> 6
<211> 34
<212> DNA
<213> Human immunodeficiency virus

<400> 6
atacatttct gcgccccggc tggttttgcg attc 34

<210> 7
<211> 26
<212> DNA
<213> Human immunodeficiency virus

<400> 7
gaagaattcc cctccacaat taaaac 26

<210> 8
<211> 37
<212> DNA
<213> Human immunodeficiency virus

<400> 8

tgtggagggg aattcttcta ctgtaataca acacaac

37

<210> 9

<211> 38

<212> DNA

<213> Human immunodeficiency virus

<400> 9

atcatcatcg gatcccgagg ttatagcaaa gccctttc

38

<210> 10

<211> 24

<212> DNA

<213> Human immunodeficiency virus

<400> 10

tagtgggaaa gagatcttca gacc

24

<210> 11

<211> 37

<212> DNA

<213> Human immunodeficiency virus

<400> 11

ttttaagctt ttatccctgc ctaactctat tcactat

37

<210> 12

<211> 24

<212> DNA

<213> Human immunodeficiency virus

<400> 12

tagtgggaaa gagatcttca gacc

24

<210> 13

<211> 47

<212> DNA

<213> Human immunodeficiency virus

<400> 13

cctcctacta tcattatgaa tattcttttt tctctctgca ccactct

47

<210> 14

<211> 48

<212> DNA

<213> Human immunodeficiency virus

<400> 14

agagtgggtgc agagagaaaa aagaatattc ataatgatag taggaggc

48

<210> 15
<211> 37
<212> DNA
<213> Human immunodeficiency virus

<400> 15
ttttaagctt ttatccctgc ctaactctat tcactat

37

<210> 16
<211> 4434
<212> DNA
<213> Human immunodeficiency virus

<400> 16
gagctcgcgg cgcctatca aaagtcttaa tgagttaggt gtagatagta tagatattac 60
tacaaaggta ttcataattc ctatcaattc taaagtagat gatattaata actcaaagat 120
gatgatagta gataatagat acgctcatat aatgactgca aatttggacg gttcacattt 180
taatcatcac gcgttcataa gtttcaactg catagatcaa aatctcacta aaaagatagc 240
cgatgtattt gagagagatt ggacatctaa ctacgctaaa gaaattacag ttataaaataa 300
tacataatgg attttggtat catcagttat atttaacata agtacaataa aaagtattaa 360
ataaaaaatac ttacttacga aaaaatgact aattagctat aaaaaccag atctctcgag 420
gtcgacggta tcgataagct tgatatcgaa ttcataaaaa ttattgatgt ctacacatcc 480
ttttgtaatt gacatctata tacccttttg tataatcaac tctaactact ttaactttta 540
cagttttccc taccagttta tccctatatt caacatatct atccatagc atcttaacac 600
tctctgcaa gatagcttca gagtggagat agtcaaaaag ataaatgtat agagcataat 660
ccttctcgta tactctgccc tttattacat cgcccgcat gggcaacgaa taacaaaatg 720
caagcatacg atacaaactt aacggatata gcgataatga aataatttat gattatttct 780
cgctttcaat ttaacacaac cctcaagaac ctttgatttt attttcaact tttaagtata 840
gaataaagaa agctctaatt aattaatgaa cagattgttt cgttttcccc ttggcgatc 900
actaattaat taaccggggc tgcagctcga ggaattcaac tatatcgaca tatttcattt 960
gtatacacat aaccattact aacgtagaat gtataggaag agatgtaacg ggaacagggt 1020
ttgttgattc gcaaactatt ctaatacata attcttctgt taatacgtct tgcacgtaat 1080
ctattataga tgccaagata tctatataat tattttgtaa gatgatgtta actatgtgat 1140
ctatataagt agtgtaataa ttcattgtat tcgatatatg ttccaactct gtctttgtga 1200
tgtctagttt cgtaatatct atagcatcct caaaaaatat attcgcatat attcccaagt 1260
cttcagttct atcttctaaa aaatcttcaa cgtatggaat ataataatct attttacctc 1320
ttctgatatc ataatgata tagtttttga cactatcttc tgtcaattga ttcttattca 1380
ctatatctaa gaaacggata gcgtccctag gacgaactac tgccattaat atctctatta 1440
tagcttctgg acataattca tctattatac cagaattaat gggaactatt ccgtatctat 1500
ctaacatagt ttttaagaaag tcagaatcta agacctgatg ttcataatatt ggttcataca 1560
tgaaatgac tctattgatg atagtgacta tttcattctc tgaaaattgg taactcattc 1620
tatatatgct ttccttggtg atgaaggata gaataactc aatagaattt gtaccaacaa 1680
actgttctct tatgaatcgt atatcatcat ctgaaataat catgtaaggc atacatttaa 1740
caattagaga cttgtctcct gttatcaata tactattctt gtgataattt atgtgtgagg 1800
caaatttgct cacgttcttt aattttgtta tagtagatat caaatccaat ggagctacag 1860
ttcttggtt aaacagatat agtttttctg gaacaaattc tacaacatta ttataaagga 1920
ctttgggtag ataagtggga tgaaatccta ttttaattaa tgctatcgca ttgtcctcgt 1980
gcaaatatcc aaacgctttt gtgatagtat ggcattcatt gtctagaaac gctctacgaa 2040
tatctgtgac agatatcatc tttagagaat atactagtcg cgtaaatagt actacaattt 2100
gtatttttta atctatctca ataaaaaat taatatgtat gattcaatgt ataactaaac 2160
tactaactgt tattgataac tagaatcaga atctaattgat gacgtaacca agaagtttat 2220
ctactgcaa tttagctgca ttatttttag catctcgttt agattttcca tctgccttat 2280
cgaatactct tccgtcgatg tctacacagg cataaaatgt aggagagtta ctaggcccaa 2340
ctgattcaat acgaaaagac caatctctct tagttatttg gcagtactca ttaataatgg 2400
tgacagggtt agcatctttc caatcaataa ttttttttagc cggaataaca tcatcaaaag 2460
acttatgatc ctctctcatt gatttttctgc gggatacatc atctattatg acgtcagcca 2520

tagcatcagc	atccggttta	tccgcctccg	ttgtcataaa	ccaacgagga	ggaatatcgt	2580
cggagctgta	caccatagca	ctacgttgaa	gatcgtacag	agctttatta	acttctcgct	2640
tctccatatt	aagttgtcta	gttagttgtg	cagcagtagc	tccttcgatt	ccaatgtttt	2700
taatagccgc	acacacaatc	tctgcgtcag	aacgctcgtc	aatatagatc	ttagacattt	2760
ttagagagaa	ctaacacaac	cagcaataaa	actgaacctc	ctttatcatt	tttttattca	2820
tcacacctcg	gtgggttcgtc	gtttctatcg	aatgtagctc	tgattaaccc	gtcatctata	2880
ggtgatgctg	gttctggaga	ttctggagga	gatggattat	tatctggaag	aatctctgtt	2940
atttccttgt	tttcatgtat	cgattgcgtt	gtaacattaa	gattgcgaaa	tgctctaaat	3000
ttgggaggct	taaagtgttg	tttgcaatct	ctacacgcgt	gtctaactag	tgagggttcg	3060
tcagctgctc	tagtttgatc	catcatcggc	gtagtattcc	tactttttaca	gttaggacac	3120
ggtgtattgt	atttctcgtc	gagaacgtta	aaataatcgt	tgtaactcac	atcctttatt	3180
ttatctatat	tgtattctac	tcctttctta	atgcatttta	taccgaataa	gagatagcga	3240
aggaattcct	tttattgatt	aactagtcaa	atgagtatat	ataattgaaa	aagtaaaata	3300
taaatcatat	aataatgaaa	cgaaatatca	gtaatagaca	ggaactggca	gattcttctt	3360
ctaatagaat	aagtactgct	aaatctccaa	aattagataa	aaatgataca	gcaaatacag	3420
cttcattcaa	cgaattacct	tttaattttt	tcagacacac	cttattacaa	actaactaag	3480
tcagatgatg	agaaagtaaa	tataaattta	acttatgggt	ataatataat	aaagattcat	3540
gatattaata	atttacttaa	cgatgttaat	agacttattc	catcaacccc	ttcaaaccct	3600
tctggatatt	ataaaatacc	agttaatgat	attaaaatag	attgtttaag	agatgtaaat	3660
aattatttgg	aggtaaagga	tataaaatta	gtctatcttt	cacatggaaa	tgaattacct	3720
aatattaata	attatgatag	gaatttttta	ggatttacag	ctgttatatg	tatcaacaat	3780
acaggcagat	ctatggttat	ggtaaaacac	tgtaacggga	agcagcattc	tatggtaact	3840
ggcctatggt	taatagccag	atcattttac	tctataaaca	ttttaccaca	aataatagga	3900
tcctctagat	atttaatat	atatctaaca	acaacaaaaa	aatttaacga	tgtatggcca	3960
gaagtatttt	ctactaataa	agataaagat	agtctatctt	atctacaaga	tatgaaagaa	4020
gataatcatt	tagtagtagc	tactaatatg	gaaagaaatg	tatacaaaaa	cgtggaagct	4080
tttatattaa	atagcatatt	actagaagat	ttaaaaacta	gacttagtat	aacaaaacag	4140
ttaaatgccca	atatcgattc	tatatttcat	cataacagta	gtacattaat	cagtgatata	4200
ctgaaacgat	ctacagactc	aactatgcaa	ggaataagca	atatgccaat	tatgtctaata	4260
atttttaactt	tagaactaaa	acgttctacc	aataactaaa	ataggatacg	tgataggctg	4320
ttaaaagctg	caataaatag	taaggatgta	gaagaaatac	tttgttctat	accttcggag	4380
gaaagaactt	tagaacaact	taagtttaat	caaacttgta	tttatgaagg	tacc	4434

<210> 17

<211> 4434

<212> DNA

<213> Human immunodeficiency virus

<400> 17

ctcgcgcgcc	ggcggatagt	tttcagaatt	actcaatcca	catctatcat	atctataatg	60
atgtttccat	aagtataaag	gatagttaag	atttcatcta	ctataattat	tgagtttcta	120
ctactatcat	ctattatcta	tgcgagtata	ttactgacgt	ttaaacctgc	caagtgtaaa	180
attagtagtg	cgcaagtatt	caaagttgac	gtatctagtt	ttagagtgat	ttttctatcg	240
gctacataaa	ctctctctaa	cctgtagatt	gatgcgattt	ctttaatgtc	aatattttatt	300
atgtattacc	taaaacaata	gtagtcaata	taaattgtat	tcattgttatt	tttcataatt	360
tattttttatg	aatgaatgct	tttttactga	ttaatcgata	tttttgggtc	tagagagctc	420
cagctgccat	agctattcga	actatagctt	aagtattttt	aataactaca	gatgtgtagg	480
aaaacattaa	ctgtagatat	ataggaaaac	atattagttg	agattagtga	aattgaaaat	540
gtcaaaaggg	atggtcaaat	agggatataa	gttgataga	taggtatacg	tagaattgtg	600
agagacgggt	ctatcgaggt	ctcactccta	tcagtttttc	tattttacata	tctcgtatta	660
ggaagagcat	atgagacggg	aaataatgta	gcgggcgtaa	cccgttgctt	attgtttttac	720
gttcgtatgc	tatgtttgaa	ttgcctatag	cgctattact	ttattaaata	ctaataaaga	780
gcgaaagtta	aattgtgttg	ggagttcttg	gaaacataaa	taaaagtga	aaattcatat	840
cttattttctt	tcgagattaa	tttaattactt	gtctaacaaa	gcaaaagggg	aaccgcatag	900
tgattaatta	attgggcccg	acgtcgagct	ccttaagttg	atatagctgt	ataaagtaaa	960
catatgtgta	ttggtaatga	ttgcatctta	catatccttc	tctacattgc	ccttgtccca	1020

aacaactaag	cgtttgataa	gattatgtat	taagaagaca	attatgcaga	acgtgcatta	1080
gataatatct	acgggttctat	agatatatta	ataaaacatt	ctactacaat	tgatacacta	1140
gatatattca	tcacattatt	aagtacataa	agctatatac	aagggttgaga	cagaaacact	1200
acagatcaaa	gcattataga	tatcgttaga	gttttttata	taagcgtata	taagggttca	1260
gaagtcaaga	tagaagattt	tttagaagtt	gcatacctta	tattattaga	taaaatggag	1320
aagactatag	taattactat	atcaaaaact	gtgatagaag	acagttaact	aagaataagt	1380
gatatagatt	ctttgcctat	cgcagggatc	ctgcttgatg	acggtaatta	tagagataat	1440
atcgaagacc	tgtattaagt	agataatatg	gtcttaatta	cccttgataa	ggcatagata	1500
gattgtatca	aaattctttc	agtcttagat	tctggactac	aagtatataa	ccaagtatgt	1560
actttactag	agataactac	tatcactgat	aaagtaagag	acttttaacc	attgagttaag	1620
atatatacga	aaggaacaac	tacttcctat	cttatatgag	ttatcttaaa	catggttggt	1680
tgacaagaga	atacttagca	tatagtagta	gactttatta	gtacattccg	tatgtaaatt	1740
gttaatctct	gaacagagga	caatagttat	atgataagaa	cactattaaa	tacacactcc	1800
gtttaaacag	gtgcaagaaa	ttaaaacaat	atcatctata	gtttagggtta	cctcgatgtc	1860
aagaaccgaa	tttgtctata	tcaaaaagac	cttgtttaag	atggttgtaat	aatatttcct	1920
gaaacccatc	tattcaccct	acttttaggat	aaaattaatt	acgatagcgt	aacaggagca	1980
cgtttatagg	tttgcgaaaa	cactatcata	ccgtaagtaa	cagatctttg	cgagatgctt	2040
atagacactg	tctatagtag	aaatctctta	tatgatcagc	gcaattatca	tgatgttaaa	2100
cataaaaaat	tagatagagt	tattttttta	attatacata	ctaagttaca	tattgatttg	2160
atgattgaca	ataactattg	atcttagtct	tagattacta	ctgcattggt	tcttcaaata	2220
gatgacgggt	aatcgcacgt	aataaaaaatc	gtagagcaaa	tctaaaagggt	agacggaata	2280
gcttatgaga	aggcagctac	agatgtgtcc	gtattttaca	tcctctcaat	gatccgggtt	2340
gactaagtta	tgcttttctg	gttagagaga	atcaataaac	cgtcatgagt	aattattacc	2400
actgtcccaa	tcgtagaaaag	gttagttatt	aaaaaaatcg	gccttattgt	agtagttttc	2460
tgaatactag	gagagagtaa	ctaaaaagcg	ccctatgtag	tagataatac	tgcagtcggg	2520
atcgttagctg	taggcgcaat	aggcggaggc	aacagtatatt	ggttgctcct	ccttatagca	2580
gcctcgacat	gtggttatcgt	gatgcaactt	ctagcatgtc	tcgaaataat	tgaagagcga	2640
agaggataaa	ttcaacagat	caatcaacac	gtcgtcatcg	aggaagctaa	ggttacaaaa	2700
attatcggcg	tgtgtgttag	agacgcagtc	ttgcgagcag	ttatatctag	aatctgtaaa	2760
aatctctctt	gattgtgttg	gtcgttattt	tgacttggtg	gaaatagtaa	aaaaataagt	2820
agtaggagac	caccaagcag	caaagatagc	ttacatcgag	actaatggg	cagtagatat	2880
ccactacgac	caagacctct	aagacctcct	ctaccttaata	atagaccttc	ttagagacaa	2940
taaaggaaca	aaagtacata	gctaacgcaa	cattgtaatt	ctaacgcttt	acgagattta	3000
aaccctccga	atttcacaac	aaacgttaga	gatgtgcgca	cagattgatc	acctccaagc	3060
agtcgacgag	atcaaaactta	gtagtagccg	catcataagg	atgaaaatgt	caatcctgtg	3120
ccacataaca	taaagagcag	ctcttgcaat	tttattagca	acattgagtg	taggaaataa	3180
aatagatata	acataagatg	aggaaagaat	tacgtaaaat	atggcttatt	ctctatcgct	3240
tccttaagaa	aaataactaa	ttgatcagtt	tactcatata	tattaacttt	ttcattttat	3300
atttagtata	ttattacttt	gctttatagt	cattatctgt	ccttgaccgt	ctaagaagaa	3360
gattacttca	ttcatgacga	tttagagggt	tttactatgt	tttactatgt	cgtttatgtc	3420
gaagtaagtt	gcttaatgga	aaattaaaaa	agtctgtgtg	gaataatggt	tgattgattc	3480
agtcctactac	tctttcattt	atattttaat	tgaataccca	tattatatta	tttctaagta	3540
ctataattat	taaatgaatt	gctacaatta	tctgaataag	gtagttgggg	aagtttgga	3600
agacctataa	tattttatgg	tcaattacta	taattttatc	taacaaattc	tctacattta	3660
ttaataaacc	tccatttcct	atattttaat	cagatagaaa	gtgtaccttt	acttaatgga	3720
ttataattat	taatactatc	cttaaaaaat	cctaaatgtc	gacaatatac	atagttgtta	3780
tgctcgtcta	gataccaata	ccattttgtg	acattgccct	tcgctgtaag	ataccattga	3840
ccggatacaa	attatcggtc	tagtaaaatg	agatatttgt	aaaatgggtg	ttattatcct	3900
aggagatcta	taaattataa	tatagattgt	tggtgttttt	ttaaattgct	acataccggg	3960
cttcataaaa	gatgattatt	tctattttcta	tcagatagaa	tagatgttct	atactttcct	4020
ctattagtaa	atcatcatcg	atgattatac	ctttctttac	atatgttttt	gcaccttcga	4080
aaatataatt	tatcgtataa	tgatcttcta	aatttttagat	ctgaatcata	ttgttttgtc	4140
aattttacgg	tatagctaag	atataaagta	gtattgtcat	catgtaatta	gtcactatat	4200
gacttttgcta	gatgtctgag	ttgatacgtt	ccttattcgt	tatacgggtta	atacagatta	4260
taaaattgaa	atcttgattt	tgcaagatgg	ttatgatttt	tatcctatgc	actatccgac	4320
aatttttcgac	gttattttatc	attcctacat	cttctttatg	aaacaagata	tggaagcctc	4380
ctttcttgaa	atcttggtga	attcaaatta	gtttgaacat	aaatacttcc	atgg	4434

<210> 18
<211> 88
<212> PRT
<213> Human immunodeficiency virus

<400> 18
Gln His Arg Cys Met Arg Lys Tyr Asn Val Asp Ile Tyr Gly Lys Thr
1 5 10 15
Tyr Asp Val Arg Ile Val Lys Val Lys Val Thr Lys Gly Val Leu Lys
20 25 30
Asp Arg Tyr Glu Val Tyr Arg Asp Met His Met Lys Val Ser Glu Ala
35 40 45
Leu Ile Ala Glu Ser His Pro Tyr Asp Phe Leu Tyr Ile Tyr Leu Ala
50 55 60
Tyr Asp Lys Glu Tyr Val Arg Gly Lys Ile Val Asp Gly Ala Asn Pro
65 70 75 80
Leu Ser Tyr Cys Phe Ala Leu Met
85

<210> 19
<211> 190
<212> PRT
<213> Human immunodeficiency virus

<400> 19
Phe Arg Ile Ile Val Tyr Gly Leu Leu Lys Asp Val Ala Leu Lys Ala
1 5 10 15
Ala Asn Asn Lys Ala Asp Arg Lys Ser Lys Gly Asp Ala Lys Asp Phe
20 25 30
Val Arg Gly Asp Ile Asp Val Cys Ala Tyr Phe Thr Pro Ser Asn Ser
35 40 45
Pro Gly Val Ser Glu Ile Arg Phe Ser Trp Asp Arg Lys Thr Ile Gln
50 55 60
Cys Tyr Glu Asn Ile Ile Thr Val Pro Asn Ala Asp Lys Trp Asp Ile
65 70 75 80
Ile Lys Lys Ala Pro Ile Val Asp Asp Phe Ser Lys His Asp Glu Arg
85 90 95
Met Ser Lys Glu Arg Ser Val Asp Asp Ile Ile Val Asp Ala Met Ala
100 105 110
Asp Ala Asp Pro Lys Asp Ala Glu Thr Thr Met Phe Trp Arg Pro Pro
115 120 125

Ile Asp Asp Ser Ser Tyr Val Met Ala Ser Arg Gln Leu Asp Tyr Leu
130 135 140

Ala Lys Asn Val Glu Arg Lys Glu Met Asn Leu Gln Arg Thr Leu Gln
145 150 155 160

Ala Ala Thr Ala Gly Glu Ile Gly Ile Asn Lys Ile Ala Ala Cys Val
165 170 175

Ile Glu Ala Asp Ser Arg Glu Asp Ile Tyr Ile Lys Ser Met
180 185 190